Moore, K. N., Oaknin Benzaquen, A. M., Friedlander, M., Lisyanskaya, A., Scambia, G., & Colombo, N. (2021). Tolerability of maintenance olaparib in newly diagnosed patients with advanced ovarian cancer and a BRCA mutation in the randomized phase III SOLO1 trial.
Citación estilo ChicagoMoore, Kathleen N., Ana Mazaltob Oaknin Benzaquen, Michael Friedlander, Alla Lisyanskaya, Giovanni Scambia, y Nicoletta Colombo. Tolerability of Maintenance Olaparib in Newly Diagnosed Patients With Advanced Ovarian Cancer and a BRCA Mutation in the Randomized Phase III SOLO1 Trial. 2021.
Cita MLAMoore, Kathleen N., et al. Tolerability of Maintenance Olaparib in Newly Diagnosed Patients With Advanced Ovarian Cancer and a BRCA Mutation in the Randomized Phase III SOLO1 Trial. 2021.